Novartis intends to localize production of 40 drugs at its plant in St Petersburg

Swiss pharma giant Novartis (NOVN: VX) intends to localize production of up to 40 drugs at its Novartis-Neva plant in the Russian St Petersburg region, according to recent statements of vice governor of St Petersburg Sergey Movchan.

Production will comprise both for generics and original drugs. The new drugs will be supplied both to the domestic and foreign markets, reports The Pharma Letter’s local correspondent.

To date, the company has already launched the production of a new an anti-inflammatory drug, the name of which is not disclosed. The launch of production took place as part of the state program "Pharma 2020", which involves replacement of drug imports in Russia by the establishment of domestic production.